Neuronetics, Inc. (NASDAQ:STIM) Shares Sold by Teton Advisors Inc.

Teton Advisors Inc. decreased its holdings in Neuronetics, Inc. (NASDAQ:STIM) by 47.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,000 shares of the company’s stock after selling 16,000 shares during the quarter. Teton Advisors Inc. owned 0.06% of Neuronetics worth $52,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of STIM. Kent Lake Capital LLC raised its holdings in Neuronetics by 229.8% in the 3rd quarter. Kent Lake Capital LLC now owns 2,329,287 shares of the company’s stock worth $3,145,000 after purchasing an additional 1,622,938 shares during the period. Millrace Asset Group Inc. raised its holdings in Neuronetics by 205.1% in the 4th quarter. Millrace Asset Group Inc. now owns 725,369 shares of the company’s stock worth $2,104,000 after purchasing an additional 487,591 shares during the period. First Eagle Investment Management LLC raised its holdings in Neuronetics by 33.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 776,009 shares of the company’s stock worth $1,048,000 after purchasing an additional 195,834 shares during the period. Thompson Siegel & Walmsley LLC acquired a new position in Neuronetics in the 4th quarter worth about $545,000. Finally, Cannell Capital LLC raised its holdings in Neuronetics by 2.4% in the 3rd quarter. Cannell Capital LLC now owns 2,833,982 shares of the company’s stock worth $3,826,000 after purchasing an additional 65,240 shares during the period. Institutional investors and hedge funds own 53.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. William Blair reiterated a “market perform” rating on shares of Neuronetics in a report on Tuesday, March 26th. Piper Sandler reiterated an “overweight” rating and issued a $8.00 price objective (up from $7.00) on shares of Neuronetics in a report on Wednesday, March 6th.

Neuronetics Trading Down 1.5 %

NASDAQ:STIM traded down $0.06 during trading hours on Thursday, reaching $3.50. 30,336 shares of the stock were exchanged, compared to its average volume of 173,893. The company has a quick ratio of 4.33, a current ratio of 4.73 and a debt-to-equity ratio of 1.73. The business has a 50-day moving average of $3.95 and a two-hundred day moving average of $2.88. Neuronetics, Inc. has a twelve month low of $1.03 and a twelve month high of $5.07. The company has a market capitalization of $104.93 million, a price-to-earnings ratio of -3.32 and a beta of 2.50.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. The company had revenue of $20.31 million for the quarter, compared to analysts’ expectations of $19.73 million. During the same period in the prior year, the firm earned ($0.30) earnings per share. On average, equities analysts predict that Neuronetics, Inc. will post -0.92 EPS for the current year.

Insiders Place Their Bets

In other Neuronetics news, EVP William Andrew Macan sold 22,377 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $3.16, for a total transaction of $70,711.32. Following the transaction, the executive vice president now directly owns 395,359 shares in the company, valued at $1,249,334.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP William Andrew Macan sold 22,377 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $3.16, for a total value of $70,711.32. Following the sale, the executive vice president now directly owns 395,359 shares in the company, valued at $1,249,334.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen Furlong sold 14,710 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $3.51, for a total value of $51,632.10. Following the completion of the sale, the chief financial officer now owns 509,033 shares in the company, valued at $1,786,705.83. The disclosure for this sale can be found here. Insiders have sold 150,279 shares of company stock worth $489,167 over the last ninety days. Corporate insiders own 9.80% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.